Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction A Meta-Analysis of Preclinical Studies and Clinical Trials

被引:141
|
作者
Kanelidis, Anthony J. [1 ]
Premer, Courtney [1 ,2 ]
Lopez, Juan [4 ]
Balkan, Wayne [1 ,3 ]
Hare, Joshua M. [1 ,3 ]
机构
[1] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Coral Gables, FL 33124 USA
[2] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Coral Gables, FL 33124 USA
[3] Univ Miami, Dept Med, Coral Gables, FL 33124 USA
[4] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA
基金
美国国家卫生研究院;
关键词
cell- and tissue-based therapy; heart failure; mesenchymal stem cell transplantation; meta-analysis; myocardial infarction; LEFT-VENTRICULAR FUNCTION; LARGE ANIMAL-MODELS; IMPROVES CARDIAC-FUNCTION; ISCHEMIC CARDIOMYOPATHY; PORCINE MODEL; TISSUE PERFUSION; HEME OXYGENASE-1; TRANSPLANTATION; HEART; INJECTION;
D O I
10.1161/CIRCRESAHA.116.309819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery. Objective: We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction (LVEF). Methods and Results: We performed a meta-analysis investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n= 1165 mouse, rat, swine) which revealed a reduction in infarct size and improvement of LVEF in all animal models. Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials; n= 334 patients). In AMI swine studies, transendocardial stem cell injection reduced infarct size (n= 49, 9.4% reduction; 95% confidence interval, -15.9 to -3.0), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicated no improvement. Similarly, transendocardial stem cell injection improved LVEF (n= 65, 9.1% increase; 95% confidence interval, 3.7 to 14.5), as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement. In humans, changes of LVEF paralleled these results, with transendocardial stem cell injection improving LVEF (n= 46, 7.0% increase; 95% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement. Conclusions: MSC therapy improves cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy. The route of delivery seems to play a role in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the superiority of transendocardial stem cell injection because of its reduction in infarct size and improvement of LVEF, which has important implications for the design of future studies.
引用
收藏
页码:1139 / +
页数:30
相关论文
共 50 条
  • [1] Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies
    Sun, Xue-Yi
    Ding, Xian-Fei
    Liang, Huo-Yan
    Zhang, Xiao-Juan
    Liu, Shao-Hua
    Bing-Han
    Duan, Xiao-Guang
    Sun, Tong-Wen
    STEM CELL RESEARCH & THERAPY, 2020, 11 (01)
  • [2] Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies
    Xue-Yi Sun
    Xian-Fei Ding
    Huo-Yan Liang
    Xiao-Juan Zhang
    Shao-Hua Liu
    Xiao-Guang Bing-Han
    Tong-Wen Duan
    Stem Cell Research & Therapy, 11
  • [3] Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials
    Armin Attar
    Fateme Bahmanzadegan Jahromi
    Shahin Kavousi
    Ahmad Monabati
    Asma Kazemi
    Stem Cell Research & Therapy, 12
  • [4] Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials
    Attar, Armin
    Bahmanzadegan Jahromi, Fateme
    Kavousi, Shahin
    Monabati, Ahmad
    Kazemi, Asma
    STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
  • [5] Mesenchymal Stem Cell Therapy in Ischemic Stroke: A Meta-analysis of Preclinical Studies
    Sarmah, Deepaneeta
    Agrawal, Vishal
    Rane, Pallavi
    Bhute, Shashikala
    Watanabe, Mitsuyoshi
    Kalia, Kiran
    Ghosh, Zhumur
    Dave, Kunjan R.
    Yavagal, Dileep R.
    Bhattacharya, Pallab
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (06) : 990 - 998
  • [6] Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies
    Deng-Yuan Li
    Ru-Fang Li
    Dan-Xiong Sun
    Dan-Dan Pu
    Yun-Hui Zhang
    Stem Cell Research & Therapy, 12
  • [7] Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies
    Li, Deng-Yuan
    Li, Ru-Fang
    Sun, Dan-Xiong
    Pu, Dan-Dan
    Zhang, Yun-Hui
    STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
  • [8] Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Yu, Jiang
    Zhang, Run-feng
    Mao, Yi-li
    Zhang, Heng
    CURRENT STEM CELL RESEARCH & THERAPY, 2022, 17 (08) : 793 - 807
  • [9] Cardiac Stem Cell Treatment in Myocardial Infarction: A Systematic Review and Meta-Analysis of Preclinical Studies
    Zwetsloot, Peter Paul
    Vegh, Anna Maria Dorothea
    Sanne Johanna Jansen of Lorkeers
    van Hout, Gerardus P. J.
    Currie, Gillian L.
    Sena, Emily S.
    Gremmels, Hendrik
    Buikema, Jan Willem
    Goumans, Marie-Jose
    Macleod, Malcolm R.
    Doevendans, Pieter A.
    Chamuleau, Steven A. J.
    Sluijter, Joost P. G.
    CIRCULATION RESEARCH, 2016, 118 (08) : 1223 - 1232
  • [10] Intracoronary mesenchymal stem cells infusion after acute myocardial infarction: a meta-analysis on clinical trials
    Jie, Qin
    Bai, Mingjun
    Mao, Yongjiang
    Jie, Qin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C116 - C117